CLL17

About this trial

This trial will compare the efficacy of continuous ibrutinib monotherapy with fixed-duration venetoclax plus obinutuzumab and fixed-duration ibrutinib plus venetoclax in patients with previously untreated CLL

Patient Profile

Patients with previously untreated Chronic Lymphocytic Leukaemia (CLL)

Where’s this trial being run?

Beaumont Hospital, Cork University Hospital, St James’s Hospital, University Hospital Waterford, and Mater Misericordiae University Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.


Summary Data

Name: CLL17
Number: 20-22
Full Title:

A Phase 3 Multicentre, Randomized, Prospective, Open-label Trial of Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Principal Investigator: Prof Patrick Thornton (Beaumont Hospital)
Type: Collaborative
Sponsor:

German CLL Study Group

Recruitment Started: Global: Feb-21
Ireland: May-21
Global Recruitment Target: 897
Ireland Recruitment Target: 40